This company has been acquired
Cyclo Therapeutics (CYTH) Stock Overview
A clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
CYTH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cyclo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.72 |
| 52 Week High | US$1.79 |
| 52 Week Low | US$0.55 |
| Beta | -0.57 |
| 1 Month Change | -6.29% |
| 3 Month Change | 20.50% |
| 1 Year Change | -48.16% |
| 3 Year Change | -76.37% |
| 5 Year Change | -96.17% |
| Change since IPO | -99.64% |
Recent News & Updates
Shareholder Returns
| CYTH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.9% | -1.0% | 1.0% |
| 1Y | -48.2% | 1.8% | 17.5% |
Return vs Industry: CYTH underperformed the US Biotechs industry which returned -8.3% over the past year.
Return vs Market: CYTH underperformed the US Market which returned 7.8% over the past year.
Price Volatility
| CYTH volatility | |
|---|---|
| CYTH Average Weekly Movement | 20.3% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CYTH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CYTH's weekly volatility has increased from 14% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 8 | N. Fine | cyclotherapeutics.com |
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company’s lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer’s disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
Cyclo Therapeutics, Inc. Fundamentals Summary
| CYTH fundamental statistics | |
|---|---|
| Market cap | US$20.73m |
| Earnings (TTM) | -US$24.80m |
| Revenue (TTM) | US$870.73k |
Is CYTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYTH income statement (TTM) | |
|---|---|
| Revenue | US$870.73k |
| Cost of Revenue | US$76.25k |
| Gross Profit | US$794.48k |
| Other Expenses | US$25.59m |
| Earnings | -US$24.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 91.24% |
| Net Profit Margin | -2,848.16% |
| Debt/Equity Ratio | -90.4% |
How did CYTH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/28 19:02 |
| End of Day Share Price | 2025/03/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cyclo Therapeutics, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |